Bipolar Depression Treatment: The FDA-Approved Options and Why Antidepressants Are Different

Five treatments are FDA-approved for the depressive phase of bipolar disorder: quetiapine, lurasidone, cariprazine, lumateperone and the olanzapine-fluoxetine combination. Lithium and lamotrigine are also first-line in the 2018 CANMAT and ISBD guidelines for bipolar I depression, although neither is FDA-approved for acute bipolar depression. Standard antidepressants are treated differently: in bipolar I disorder, an international task force advised using them only alongside a mood-stabilizing medicine, not on their own.

Structured psychotherapy, such as interpersonal and social rhythm therapy, family-focused therapy or CBT, adds benefit when combined with medication. The newest bipolar medicine, milsaperidone (Bysanti, first approved in 2026), is indicated for mania, not bipolar depression.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

The FDA-approved options side by side

All five are second-generation antipsychotics or contain one. They share a boxed warning about increased risk of death in older adults with dementia-related psychosis, and a boxed warning about suicidal thoughts and behaviors in children, adolescents and young adults taking antidepressant-class treatments. Weight gain, raised blood sugar and lipid changes are class concerns, though each medicine has its own profile. Two practical differences often guide the choice: whether you have bipolar I or II, since only quetiapine and lumateperone were approved on trials that included bipolar II, and whether you are already on lithium or valproate, since lurasidone and lumateperone are labeled as add-ons to them. The guide to antipsychotic metabolic monitoring explains the checks that come with these medicines.

Why antidepressants are handled differently

Antidepressants are widely prescribed in bipolar disorder, but the evidence supporting them is weak. An expert task force of the International Society for Bipolar Disorders described a "striking incongruity" between how often they are used and how little evidence supports their efficacy and safety in bipolar disorder. Its main concern was a switch from depression into hypomania, mania or a mixed state.

The largest effectiveness trial tested this directly. People with bipolar depression already on a mood stabilizer were randomized to add a standard antidepressant or a placebo for up to 26 weeks. Durable recovery occurred in 23.5% with the antidepressant and 27.3% with placebo, a difference that was not statistically significant. Switch rates were similar in both groups, so the antidepressant neither helped nor clearly harmed in that setting.

The task force concluded:

• in bipolar I disorder, antidepressants should be prescribed only as an add-on to mood-stabilizing medication;
• switches appear more frequent and severe in bipolar I than bipolar II;
• SSRIs and bupropion may carry lower switch rates than tricyclics and SNRIs;
• individual patients may still benefit, so the decision is case by case.

The FDA labels reflect this caution. Antidepressant labels instruct prescribers to screen for a personal or family history of bipolar disorder, mania or hypomania before starting. Fluoxetine's label states that fluoxetine alone is not indicated for bipolar depression; only its combination with olanzapine is. If you have been treated for "depression" with several antidepressants and had periods of unusually high energy, little need for sleep or racing thoughts, raise this with your prescriber. The practice's article on bipolar disorder vs depression explains the overlap.

Comparing side effects among the approved options

Because the approved medicines have broadly similar evidence, side effects often decide the choice. The labels list these as the most common adverse reactions in trials, meaning at least 5% of patients and at least twice the placebo rate:

In practice, this means a person for whom weight gain would be a serious problem may lean away from quetiapine or olanzapine-fluoxetine, while someone who is very sensitive to restlessness may want to discuss the akathisia reported with lurasidone and cariprazine. Sedation can be a drawback in the daytime, or a reason to take a medicine at night; your prescriber can explain how timing is handled. These lists are not complete, and the full label covers less common but serious risks.

Why getting the diagnosis right matters

Depressive episodes of bipolar disorder can look identical to unipolar major depression, and a person may be treated for depression for some time before a manic or hypomanic episode is recognized. That is why antidepressant labels tell prescribers to ask about personal and family history of bipolar disorder, mania or hypomania before starting. Useful details to bring to an evaluation include past periods of unusually elevated or irritable mood, reduced need for sleep with high energy, rapid speech or racing thoughts, a family history of bipolar disorder, and any time an antidepressant seemed to make you feel "wired" rather than better. A diagnosis of bipolar II depends on recognizing hypomania, which can feel like a productive stretch rather than a symptom. The practice's article on why bipolar disorder gets misdiagnosed explains common reasons.

Pregnancy and planning ahead

Treatment choices narrow if pregnancy is possible. Valproate can cause major birth defects and lower IQ after exposure in pregnancy, and its label says it should not be used in women of childbearing potential unless other medicines have failed or are unacceptable. The lithium label notes early reports of heart malformations with first-trimester exposure, with later studies suggesting the added risk is likely small, and concerns about toxicity late in pregnancy and after delivery. Because stopping medication abruptly can also be risky, the safest approach is to plan with your prescriber before conception where possible. The guide to psychiatric medications during pregnancy lists the questions to raise.

Lithium and lamotrigine

Lithium's FDA indications are acute mania and maintenance in bipolar I disorder, so using it for acute bipolar depression is off-label. CANMAT and ISBD nonetheless list lithium as a first-line option for bipolar I depression, and lurasidone combined with lithium or divalproex as another. Lithium requires blood-level monitoring and kidney and thyroid checks.

Lamotrigine is approved for bipolar I maintenance, to delay mood episodes, and its label says effectiveness for acute mood episodes has not been established. It is still listed first-line for bipolar I depression in the CANMAT and ISBD guidelines, alone or as an add-on. Because it must be started slowly to reduce the risk of serious rash, it is better suited to building longer-term protection than to rapid relief. The comparison in lithium vs lamotrigine goes further, and bipolar disorder medications compared covers the full range.

Psychotherapy for bipolar depression

Medication is the foundation, but structured therapy adds measurable benefit. In a STEP-BD trial of 293 outpatients with bipolar I or II depression, people who received up to 30 sessions of intensive psychotherapy over 9 months, using family-focused therapy, interpersonal and social rhythm therapy (IPSRT) or CBT, recovered faster than those who received a brief 3-session psychoeducation program. Year-end recovery rates were 64.4% versus 51.5%, and the three intensive therapies did not differ from one another.

A 2021 network meta-analysis of 39 randomized trials with 3,863 participants found that manualized psychotherapies added to medication were associated with fewer recurrences than control treatments. Psychoeducation delivered in a family or group format did better than individual formats for preventing recurrence, and CBT was associated with stabilizing depressive symptoms, with less certain support for family and interpersonal therapy.

The practice has a related article on CBT for bipolar disorder, and the guide to interpersonal therapy for depression describes the interpersonal approach that IPSRT builds on.

When first-line treatment isn't enough

If depression persists after an adequate trial, the usual next steps are to check the basics, then adjust:

1. Confirm the diagnosis, including bipolar II versus bipolar I and any mixed features, and review for medical causes such as thyroid problems.
2. Check that the medicine was taken consistently at an adequate dose for long enough, and that lithium levels, if relevant, were in range.
3. Look for contributors: alcohol or drug use, sleep disruption, and medicines that may worsen mood.
4. Switch to or add another first-line option, guided by your history and side effects.
5. For severe or treatment-resistant depression, electroconvulsive therapy (ECT) is FDA-cleared for severe depressive episodes in people 13 and older with depression or bipolar disorder, and is usually considered when other treatments have not helped.

Whatever is added, it helps to agree in advance on the signs of a switch toward mania or hypomania that should prompt a call: sleeping much less without feeling tired, unusual talkativeness or racing thoughts, spending or risk-taking that is out of character, and irritability that is new for you. The ISBD task force identified mood switching as the main safety concern with antidepressants, so these signs matter most when one is part of the plan. Writing them down with a family member or partner makes them easier to act on.

All of these steps are decisions for your prescriber. If you are wondering whether your plan is working, see signs your mental health treatment isn't working.

Lifestyle measures that support treatment

Regular sleep and daily routines are the focus of IPSRT, one of the three therapies tested in the STEP-BD trial. Practical steps people often discuss with their clinicians include keeping consistent wake times, tracking mood and sleep daily, limiting alcohol, and agreeing with family on early-warning signs of both depression and mania. These measures support medication; they are not a substitute for it. The practice's article on sleep and circadian rhythms in bipolar disorder explores this further.

Questions to ask your prescriber

• Do I have bipolar I or II, and does that change which medicine you would choose?
• Is the medicine you are suggesting FDA-approved for bipolar depression, or is it off-label?
• If you are adding an antidepressant, which mood stabilizer covers me, and what signs of a switch should I watch for?
• What metabolic or blood tests will we do, and when?
• How long before we judge whether it is working?
• Would structured therapy such as IPSRT or family-focused therapy help me, and who provides it?

Having a written plan for a crisis is worthwhile even when you feel well; see safety planning for suicidal thoughts.

What the evidence does not show

• The approvals rest mainly on comparisons with placebo, so they do not establish which of the FDA-approved options works best overall.
• Fewer medicines are approved for bipolar II depression than for bipolar I depression; of the five, only quetiapine and lumateperone cover it.
• Antidepressants have not been shown to add durable benefit to mood stabilizers in the largest trial, but that does not mean no individual ever benefits.
• Psychotherapy research supports therapy as an add-on to medication, not as a replacement for it in bipolar disorder.

How this practice approaches bipolar depression

The practice's ongoing care includes psychiatric evaluation and medication management, psychotherapy including CBT and DBT, lab testing, and nutrition and lifestyle psychiatry, with prescribers and psychotherapists on one team. Read more on the practice's bipolar disorder treatment page, and start with the Patient Interest Form. Further decision guides are in Choosing Psychiatric Care.

Frequently asked questions

What is the first-line treatment for bipolar depression?

The 2018 CANMAT and ISBD guidelines list quetiapine, lithium, lamotrigine, lurasidone, lurasidone with lithium or divalproex, and adjunctive lamotrigine as first-line for bipolar I depression. The FDA-approved options are quetiapine, lurasidone, cariprazine, lumateperone and olanzapine-fluoxetine.

Can I take an antidepressant if I have bipolar disorder?

Sometimes, but differently from unipolar depression. An international task force advised that in bipolar I disorder antidepressants be used only together with a mood-stabilizing medicine, and the largest trial found adding one did not improve recovery. Your prescriber will weigh this for you.

Which bipolar depression medicines are approved for bipolar II?

Quetiapine's approval was based on trials that included bipolar I and II, and lumateperone is approved for bipolar I or II depression. Lurasidone, cariprazine and olanzapine-fluoxetine are approved for bipolar I depression.

How long does bipolar depression treatment take to work?

It varies by medicine and person. Quetiapine's approval for bipolar depression rested on 8-week trials, and your prescriber will set a time frame for judging response.

Is lamotrigine good for bipolar depression?

It is listed first-line for bipolar I depression in the CANMAT and ISBD guidelines, but its FDA approval is for maintenance, and its label says effectiveness for acute episodes has not been established. It must be started slowly because of rash risk.

Is therapy enough on its own for bipolar depression?

The trials that support IPSRT, family-focused therapy and CBT tested them alongside medication, so therapy is generally used as an add-on rather than a replacement.

Sources

1. SEROQUEL (quetiapine) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
2. SEROQUEL XR (quetiapine extended-release) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
3. LATUDA (lurasidone) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
4. VRAYLAR (cariprazine) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
5. CAPLYTA (lumateperone) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
6. Olanzapine and fluoxetine capsules prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
7. PROZAC (fluoxetine capsules) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
8. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry (PubMed 24030475), 2013. pubmed.ncbi.nlm.nih.gov
9. Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine (PubMed 17392295), 2007. pubmed.ncbi.nlm.nih.gov
10. ZOLOFT (sertraline) prescribing information. DailyMed / U.S. FDA label, 2023. dailymed.nlm.nih.gov
11. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders (PubMed 29536616), 2018. pubmed.ncbi.nlm.nih.gov
12. Lithium carbonate tablets and capsules prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
13. LAMICTAL (lamotrigine) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
14. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Archives of General Psychiatry (PubMed 17404119), 2007. pubmed.ncbi.nlm.nih.gov
15. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry (PubMed 33052390), 2021. pubmed.ncbi.nlm.nih.gov
16. Brain Stimulation Therapies. National Institute of Mental Health, 2026. nimh.nih.gov
17. BYSANTI (milsaperidone) tablets prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
18. DEPAKOTE (divalproex sodium) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.